Pfizer/Neurocrine File First Indiplon NDA With Eye On Fourth Quarter 2005 Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing for immediate-release formulation of insomnia agent will be followed by extended-release submission in November, Neurocrine says. A simultaneous launch is planned. Firms are highlighting long-term use, middle-of-the-night dosing.
You may also be interested in...
Takeda’s Sleep Aid Rozerem Could Avoid Controlled Substance Scheduling, Firm Says
The insomnia agent ramelteon uses a different mechanism of action than Sanofi-Aventis’ Ambien and Sepracor’s Lunesta, both of which are Schedule IV substances. Rozerem NDA is pending at FDA with a July 22 user fee date.
Takeda’s Sleep Aid Rozerem Could Avoid Controlled Substance Scheduling, Firm Says
The insomnia agent ramelteon uses a different mechanism of action than Sanofi-Aventis’ Ambien and Sepracor’s Lunesta, both of which are Schedule IV substances. Rozerem NDA is pending at FDA with a July 22 user fee date.
Sanofi-Aventis Eyes Summer Launch For Ambien CR
Discussions with FDA following an "approvable" letter for the sleep therapy have revolved around labeling for treatment duration, the company says. A summer launch would put Ambien CR's introduction several months behind that of Sepracor's Lunesta, which entered the insomnia market in early April.